Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Antisense Therapeutics Limited

Company price
None USD 0.00(0%)
Last update at 2025-01-26T19:02:55.523371Z
Market Cap
92.64M

Momentum Score

…

Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company's product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, asthma, and other inflammatory indications. Its product pipeline also includes Atesidorsen (ATL1103), an oligonucleotide targeting growth hormone receptor designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.01
Low
0.07
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
2.97M
Revenue Per Share
0.00
Gross Profit TTM
1.55M
Debt / Equity
0.00
ROE
-123.27%
Net Debt
-11.83M
ROCE
-127.02%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Income before tax -11.92M -11.38M -5.81M -8.06M -5.91M
Net income -11.92M -11.38M -5.81M -8.06M -5.91M
Selling general administrative 0.55M 3.05M 2.92M 3.56M 4.46M
Selling and marketing expenses 1.38M 1.32M 1.14M 0.84M 0.63M
Gross profit 2.91M 1.48M 1.69M 0.47M 0.56M
Reconciled depreciation 0.08M 0.10M 0.09M 0.10M 0.11M
Ebit -11.91M -11.46M -5.92M -8.20M -6.67M
Ebitda -11.90M -11.37M -5.83M -8.10M -6.56M
Depreciation and amortization 0.01M 0.10M 0.09M 0.10M 0.11M
Operating income -11.83M -13.34M -7.61M -8.68M -6.67M
Other operating expenses 14.80M 13.34M 7.61M 8.68M 6.67M
Interest expense 0.00M 0.01M 0.01M 0.01M 0.01M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.62M 0.38M 0.03M 0.00M 0.03M
Net interest income 0.61M 0.38M 0.02M -0.01M 0.02M
Income tax expense -2.35M -0.38M -0.02M 0.01M -0.02M
Total revenue 2.97M 1.58M 1.78M 0.58M 0.67M
Total operating expenses 14.74M 13.34M 7.61M 8.68M 6.67M
Cost of revenue 0.06M 0.10M 0.09M 0.10M 0.11M
Total other income expense net -0.09M -0.09M -0.07M -0.06M 0.74M
Net income from continuing ops -11.92M -11.38M -5.81M -8.06M -5.91M
Net income applicable to common shares - -11.38M -5.81M -8.06M -5.91M
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 14.53M 12.84M 22.44M 7.00M 5.35M
Other current assets 0.04M - 0.53M - 0.26M
Total liab 5.17M 2.87M 1.30M 1.27M 0.82M
Total stockholder equity 9.36M 9.98M 21.14M 5.73M 4.53M
Other current liab 1.38M 1.70M 0.74M 0.81M 0.58M
Common stock 109.37M 98.26M 98.13M 77.03M 69.15M
Capital stock 109.37M 98.26M 98.13M 77.03M 69.15M
Retained earnings -101.73M -92.29M -80.91M -75.10M -67.04M
Other liab - 0.01M 0.00M 0.00M -
Other assets 0.00M - - - -
Cash 11.87M 10.97M 19.23M 6.02M 4.06M
Total current liabilities 5.15M 2.81M 1.16M 1.05M 0.80M
Net debt -11.83M -10.83M -19.01M -5.71M -3.92M
Short term debt 0.04M 0.09M 0.09M 0.08M 0.11M
Short long term debt total 0.04M 0.14M 0.23M 0.31M 0.14M
Other stockholder equity - 4.00M 3.92M 3.79M 2.42M
Property plant equipment - 0.15M 0.22M 0.30M 0.14M
Total current assets 14.47M 12.69M 22.22M 6.70M 5.21M
Net tangible assets - 9.98M 21.14M 5.73M 4.53M
Net receivables 2.51M 1.66M 1.84M 0.60M 0.69M
Inventory - - 0.61M - 0.21M
Accounts payable 3.73M 1.02M 0.33M 0.16M 0.11M
Accumulated other comprehensive income 1.72M 4.00M 3.92M 3.79M 2.42M
Non currrent assets other -0.00M - - - -
Non current assets total 0.06M 0.15M 0.22M 0.30M 0.14M
Capital lease obligations 0.04M 0.14M 0.23M 0.31M 0.14M
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Investments -0.00M -0.03M -0.00M -0.01M -0.01M
Change to liabilities - 1.76M 0.03M 0.22M -0.26M
Total cashflows from investing activities - -0.03M -0.00M -0.01M -0.01M
Net borrowings - -0.09M -0.08M -0.08M -0.10M
Total cash from financing activities 11.02M -0.09M 21.02M 7.80M 5.11M
Change to operating activities - 0.77M -1.00M 0.45M 0.03M
Net income -11.92M -11.38M -5.81M -8.06M -5.91M
Change in cash 0.90M -8.27M 13.21M 1.96M 1.16M
Begin period cash flow 10.97M 19.23M 6.02M 4.06M 2.90M
End period cash flow 11.87M 10.97M 19.23M 6.02M 4.06M
Total cash from operating activities -10.12M -8.15M -7.81M -5.83M -3.95M
Issuance of capital stock 11.61M - 22.59M 8.50M 5.49M
Depreciation 0.08M 0.10M 0.09M 0.10M 0.11M
Change to inventory - - - - -0.00M
Change to account receivables -0.83M 0.34M -1.24M 0.09M -0.34M
Sale purchase of stock -0.50M - -1.49M -0.61M -0.29M
Other cashflows from financing activities -0.09M -0.09M -0.08M -0.08M -0.10M
Change to netincome - 0.26M 0.12M 1.37M 2.42M
Capital expenditures 0.00M 0.03M 0.00M 0.01M 0.01M
Change in working capital 1.53M 2.87M -2.21M 0.76M -0.56M
Stock based compensation 0.20M 0.21M 0.12M 1.37M 2.42M
Other non cash items -1.19M 0.26M 0.12M 1.37M 2.42M
Free cash flow -10.12M -8.18M -7.81M -5.84M -3.96M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MKKGY
Merck KGaA ADR
-0.68
2.09%
31.83 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien
-
-%
163.45 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR
0.38
1.77%
21.79 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.
-
-%
43.05 - 10.66 0.01 1.16 2.94 23.11

Profile*

Antisense Therapeutics Limited

Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company's product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, asthma, and other inflammatory indications. Its product pipeline also includes Atesidorsen (ATL1103), an oligonucleotide targeting growth hormone receptor designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

L30, Collins Place, Melbourne, VIC, Australia, 3000

61 3 9827 8999

Name Title Year Born
Mr. Mark Diamond B.Sc., M.B.A., BSc, MBA, MAICD CEO, MD & Director NA
Mr. Phillip Allen Hains BBus(Acc), CA, MBA CFO & Joint Company Sec. 1959
Dr. George Tachas Director of Drug Discovery & Patents NA
Ms. Nuket Desem Director of Clinical and Regulatory affairs NA
Dr. Anthony Filippis Chief Commercial Officer NA
Ms. Alicia Mellors Joint Company Sec. NA
Dr. James Garner B.Sc (Hons), B.Sc., M.A., M.A.I.C.D., M.B.A., MBA CEO, MD & Director 1973
Ms. Deborah Ambrosini B.Com., F.C.A. Company Secretary & CFO 1974
Dr. Anthony Filippis Chief Operating Officer NA
Dr. Cathryn M. Clary M.B.A., M.D. Chief Medical Advisor NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…